{"id":65034,"date":"2026-05-12T14:05:57","date_gmt":"2026-05-12T06:05:57","guid":{"rendered":"https:\/\/flcube.com\/?p=65034"},"modified":"2026-05-12T14:05:58","modified_gmt":"2026-05-12T06:05:58","slug":"zhejiang-shapuaisi-acquires-myopia-treatment-technology-from-wenzhou-medical-university-eye-hospital-for-10-million-plus-royalties","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65034","title":{"rendered":"Zhejiang Shapuaisi Acquires Myopia Treatment Technology from Wenzhou Medical University Eye Hospital for $10 Million Plus Royalties"},"content":{"rendered":"\n<p><strong>Zhejiang Shapuaisi Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/603168:SHA\">SHA: 603168<\/a>) announced it has entered into a comprehensive <strong>technology transfer agreement<\/strong> with <strong>Eye Hospital, Wenzhou Medical University (WMU)<\/strong> for the development of <strong>SPAS-26021<\/strong>, an innovative therapeutic approach for <strong>myopia treatment<\/strong>. The transaction includes transfer of all <strong>10 core patents<\/strong>, proprietary know-how, and related intellectual property rights for a total consideration of <strong>RMB 71 million ($10 million)<\/strong> plus post-commercialization sales royalties.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-details\">Transaction Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Zhejiang Shapuaisi Pharmaceutical Co., Ltd. and Eye Hospital, Wenzhou Medical University<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>&#8220;A method for treating myopia using SPAS-26021&#8221; \u2013 complete IP package<\/td><\/tr><tr><td><strong>IP Transferred<\/strong><\/td><td>10 core patents + proprietary know-how + related rights<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>RMB 71 million (USD 10 million)<\/td><\/tr><tr><td><strong>Additional Consideration<\/strong><\/td><td>Sales royalties post-commercialization<\/td><\/tr><tr><td><strong>Therapeutic Area<\/strong><\/td><td>Myopia (nearsightedness) treatment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-innovation\">Product Profile &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology Platform:<\/strong> SPAS-26021 \u2013 novel myopia treatment methodology developed at WMU Eye Hospital<\/li>\n\n\n\n<li><strong>Intellectual Property:<\/strong> Comprehensive patent portfolio covering method of use, formulation, and potentially delivery mechanisms<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Preclinical\/early clinical (specific stage not disclosed)<\/li>\n\n\n\n<li><strong>Market Opportunity:<\/strong> Addresses China&#8217;s myopia epidemic affecting over 50% of adolescents and young adults<\/li>\n\n\n\n<li><strong>Therapeutic Innovation:<\/strong> Potential first-in-class pharmacological approach to myopia progression control, distinct from current optical interventions<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance\">Strategic Significance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Myopia Epidemic<\/strong><\/td><td>China faces unprecedented myopia rates with ~700 million affected individuals; urgent need for effective treatments<\/td><\/tr><tr><td><strong>Academic-Industry Translation<\/strong><\/td><td>Exemplifies successful commercialization of university-developed medical innovations<\/td><\/tr><tr><td><strong>IP Strategy<\/strong><\/td><td>Complete patent portfolio acquisition provides strong market exclusivity and freedom-to-operate<\/td><\/tr><tr><td><strong>Revenue Model<\/strong><\/td><td>Upfront payment + royalty structure aligns incentives between academic institution and commercial developer<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The acquisition represents a significant strategic move by Shapuaisi to enter the high-growth ophthalmic therapeutics market, leveraging WMU Eye Hospital&#8217;s world-renowned expertise in myopia research and clinical care.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Myopia Market:<\/strong> Estimated $2\u20133 billion annual market for myopia control products with double-digit growth projected<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Limited pharmacological options currently available; most treatments rely on optical methods (glasses, contact lenses, ortho-k)<\/li>\n\n\n\n<li><strong>Regulatory Pathway<\/strong> | Category 1 innovative drug classification likely, enabling priority review and market exclusivity<\/li>\n\n\n\n<li><strong>Global Potential<\/strong> | Successful development could address myopia epidemics across Asia-Pacific and globally<\/li>\n\n\n\n<li><strong>Financial Impact<\/strong> | Modest upfront investment relative to potential peak sales; royalty structure minimizes downside risk<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding technology acquisition, development timelines, regulatory pathways, and commercial expectations for SPAS-26021. Actual results may differ due to risks including clinical development outcomes, regulatory decisions, competitive dynamics, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/603168_20260403_BW1B.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 603168_20260403_BW1B.\"><\/object><a id=\"wp-block-file--media-144a9780-90f1-43ca-ba7e-b52756ab75e0\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/603168_20260403_BW1B.pdf\">603168_20260403_BW1B<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/603168_20260403_BW1B.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-144a9780-90f1-43ca-ba7e-b52756ab75e0\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Zhejiang Shapuaisi Pharmaceutical Co., Ltd. (SHA: 603168) announced it has entered into a comprehensive technology&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[44,4731,4730],"class_list":["post-65034","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-ophthalmology","tag-sha-603168","tag-shapuaisi-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zhejiang Shapuaisi Acquires Myopia Treatment Technology from Wenzhou Medical University Eye Hospital for $10 Million Plus Royalties - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Zhejiang Shapuaisi Pharmaceutical Co., Ltd. (SHA: 603168) announced it has entered into a comprehensive technology transfer agreement with Eye Hospital, Wenzhou Medical University (WMU) for the development of SPAS-26021, an innovative therapeutic approach for myopia treatment. The transaction includes transfer of all 10 core patents, proprietary know-how, and related intellectual property rights for a total consideration of RMB 71 million ($10 million) plus post-commercialization sales royalties.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65034\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zhejiang Shapuaisi Acquires Myopia Treatment Technology from Wenzhou Medical University Eye Hospital for $10 Million Plus Royalties\" \/>\n<meta property=\"og:description\" content=\"Zhejiang Shapuaisi Pharmaceutical Co., Ltd. (SHA: 603168) announced it has entered into a comprehensive technology transfer agreement with Eye Hospital, Wenzhou Medical University (WMU) for the development of SPAS-26021, an innovative therapeutic approach for myopia treatment. The transaction includes transfer of all 10 core patents, proprietary know-how, and related intellectual property rights for a total consideration of RMB 71 million ($10 million) plus post-commercialization sales royalties.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65034\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-12T06:05:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-12T06:05:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65034#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65034\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zhejiang Shapuaisi Acquires Myopia Treatment Technology from Wenzhou Medical University Eye Hospital for $10 Million Plus Royalties\",\"datePublished\":\"2026-05-12T06:05:57+00:00\",\"dateModified\":\"2026-05-12T06:05:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65034\"},\"wordCount\":403,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Ophthalmology\",\"SHA: 603168\",\"Shapuaisi Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65034#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65034\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65034\",\"name\":\"Zhejiang Shapuaisi Acquires Myopia Treatment Technology from Wenzhou Medical University Eye Hospital for $10 Million Plus Royalties - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-12T06:05:57+00:00\",\"dateModified\":\"2026-05-12T06:05:58+00:00\",\"description\":\"Zhejiang Shapuaisi Pharmaceutical Co., Ltd. (SHA: 603168) announced it has entered into a comprehensive technology transfer agreement with Eye Hospital, Wenzhou Medical University (WMU) for the development of SPAS-26021, an innovative therapeutic approach for myopia treatment. The transaction includes transfer of all 10 core patents, proprietary know-how, and related intellectual property rights for a total consideration of RMB 71 million ($10 million) plus post-commercialization sales royalties.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65034#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65034\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65034#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zhejiang Shapuaisi Acquires Myopia Treatment Technology from Wenzhou Medical University Eye Hospital for $10 Million Plus Royalties\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zhejiang Shapuaisi Acquires Myopia Treatment Technology from Wenzhou Medical University Eye Hospital for $10 Million Plus Royalties - Insight, China&#039;s Pharmaceutical Industry","description":"Zhejiang Shapuaisi Pharmaceutical Co., Ltd. (SHA: 603168) announced it has entered into a comprehensive technology transfer agreement with Eye Hospital, Wenzhou Medical University (WMU) for the development of SPAS-26021, an innovative therapeutic approach for myopia treatment. The transaction includes transfer of all 10 core patents, proprietary know-how, and related intellectual property rights for a total consideration of RMB 71 million ($10 million) plus post-commercialization sales royalties.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65034","og_locale":"en_US","og_type":"article","og_title":"Zhejiang Shapuaisi Acquires Myopia Treatment Technology from Wenzhou Medical University Eye Hospital for $10 Million Plus Royalties","og_description":"Zhejiang Shapuaisi Pharmaceutical Co., Ltd. (SHA: 603168) announced it has entered into a comprehensive technology transfer agreement with Eye Hospital, Wenzhou Medical University (WMU) for the development of SPAS-26021, an innovative therapeutic approach for myopia treatment. The transaction includes transfer of all 10 core patents, proprietary know-how, and related intellectual property rights for a total consideration of RMB 71 million ($10 million) plus post-commercialization sales royalties.","og_url":"https:\/\/flcube.com\/?p=65034","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-12T06:05:57+00:00","article_modified_time":"2026-05-12T06:05:58+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65034#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65034"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zhejiang Shapuaisi Acquires Myopia Treatment Technology from Wenzhou Medical University Eye Hospital for $10 Million Plus Royalties","datePublished":"2026-05-12T06:05:57+00:00","dateModified":"2026-05-12T06:05:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65034"},"wordCount":403,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Ophthalmology","SHA: 603168","Shapuaisi Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65034#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65034","url":"https:\/\/flcube.com\/?p=65034","name":"Zhejiang Shapuaisi Acquires Myopia Treatment Technology from Wenzhou Medical University Eye Hospital for $10 Million Plus Royalties - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-12T06:05:57+00:00","dateModified":"2026-05-12T06:05:58+00:00","description":"Zhejiang Shapuaisi Pharmaceutical Co., Ltd. (SHA: 603168) announced it has entered into a comprehensive technology transfer agreement with Eye Hospital, Wenzhou Medical University (WMU) for the development of SPAS-26021, an innovative therapeutic approach for myopia treatment. The transaction includes transfer of all 10 core patents, proprietary know-how, and related intellectual property rights for a total consideration of RMB 71 million ($10 million) plus post-commercialization sales royalties.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65034#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65034"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65034#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zhejiang Shapuaisi Acquires Myopia Treatment Technology from Wenzhou Medical University Eye Hospital for $10 Million Plus Royalties"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65034","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65034"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65034\/revisions"}],"predecessor-version":[{"id":65036,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65034\/revisions\/65036"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65034"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65034"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65034"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}